Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Defined Bioscience

San Diego maker of fully defined, serum-free stem cell media that lower cost and variability for iPSC research and biomanufacturing.

San Diego, California, United States, North AmericaBiotech & life sciences, Serum-free culture media for stem cells
Stage
Pre-seedNo documented AI
Product
On the marketFirst customers
Funding raised
$1.5Mdisclosed
Founded
20197 years ago
Founders
5Steve, Jerome…
Global score
4.8Grade DRank 48 of 151

Overview

Defined Bioscience develops and sells defined, serum-free culture media (e.g. HiDef-B8) and reagents for pluripotent stem cell culture, for research and biomanufacturing.

Traction

First customers

Range of 11 media and reagents on sale, used by laboratories (UC San Diego, Tufts, Penn State, Vala Sciences…).

Market

Stem cell culture media

Stem cell labs and cell-therapy developers spend heavily on culture media, and serum-based or poorly defined media introduce variability that complicates manufacturing and regulatory filings. Defined, serum-free media with stabilised growth factors cut cost and improve reproducibility, which matters more as iPSC-derived therapies approach the clinic. Buyers are lab heads in academia and process-development teams in biotech, purchasing recurring consumables. The market is dominated by large reagent suppliers.

Addressable market

2025
$0.8B
2030
$1.4B
+13.44% a year

Stem cell culture media: $757M in 2025, +13.4%/year (Straits Research); other sources up to $2.3–6.5bn.

Customers

Academic stem cell labs (UC San Diego, Tufts, Penn State), biotech companies (Vala Sciences), iPSC cell-therapy developers.

Who signs the cheque

Principal investigators and lab managers; process-development and procurement heads in biotech.

Geographies

  • United States

Drivers

  • iPSC-derived therapies moving toward clinical trials
  • Pressure to reduce culture costs
  • Regulatory preference for defined, xeno-free inputs

Headwinds

  • Competition from Thermo Fisher and STEMCELL
  • Limited commercial resources
  • Need for GMP-grade products for clinical customers

The stem cell culture media market is valued at $757M in 2025 (+13.4%/year, $2.35bn in 2034) according to Straits Research; other sources go up to $2.3–6.5bn.

Scalability 7/10. Reagents that can be shipped worldwide via distributors; constraint: highly competitive niche market (Thermo, STEMCELL).

Market source: straitsresearch.com

Technology

Category

Life-science reagents (cell culture media)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

Fully defined media formulations use stabilised growth factors to maintain pluripotent stem cells without serum. The product range covers 11 media and reagents for research and biomanufacturing.

Moat

Modest: formulation and growth-factor stabilisation know-how with academic credibility (UCSD Stem Cell Program link), but switching costs are low until a customer locks a media into a regulated process.

Differentiation

Lower cost and variability versus serum-based media; independent alternative to incumbent suppliers.

Integration points

  • Cell-therapy process development
  • Bioreactor and automation platforms
  • Life-science distributors
  • Microgravity and research platforms

Depends on

  • Recombinant growth factor supply
  • GMP manufacturing capacity
  • Regulatory documentation for clinical use

Use of AI

No use of AI mentioned

Product in detail

Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.

Business

Model
Recurring consumable sales of media and reagents.
Revenue logic
Price per bottle/litre; recurring as labs scale cultures (revenue not disclosed).
Go-to-market
Direct sales to academic and biotech labs; NIH SBIR funding for development.

Next milestones

  1. GMP-grade media with regulatory documentation
  2. Design-in at a cell-therapy company heading to clinic
  3. Distribution partner in Europe or Asia

Key risks

  • Incumbent competition
  • Small sales capacity
  • Customer churn without process lock-in

Opportunities

3 found in the network

Concrete moves for Defined Bioscience inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Co-development 1
  • Investors 1

Customers1

Who could buy, or sell through

Design-in before StemSight's clinical process is locked

StemSight is developing iPSC-derived corneal cells with clinical trials targeted around 2027; media choice now will be locked into its regulated process. A collaboration to qualify Defined Bioscience media for its differentiation protocol could create a long-term clinical customer and generate comparative data.

35%confidence

Evidence from the records

  • “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
  • “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
If it works
A clinical-stage reference customer and recurring media volume through trials.
First step
Offer StemSight free evaluation kits of HiDef-B8 with a joint comparison protocol.

Co-development1

An integration or joint product

Stem cell culture in microgravity research programmes

G-Space helps biotech companies identify where microgravity offers a commercial advantage and works with Redwire, Voyager and tissue-chip projects. Defined, low-variability media are valuable for space experiments where every run is expensive; a joint offering could put Defined Bioscience into microgravity biomanufacturing studies.

15%confidence

Evidence from the records

  • “Range of 11 media and reagents on sale”
  • “helps biotech and materials companies identify where microgravity offers a commercial advantage and scale up”
  • “NASA SBIR Phase I grant (tissue chips)”
If it works
A niche but high-visibility application and introductions to space-biotech customers.
First step
Ask G-Space which of its clients run stem cell experiments and propose a joint application note.

Investors1

A fund whose thesis fits

Seed round from a science-focused US biotech investor

Defined Bioscience has only an NIH SBIR grant and needs capital for GMP products and sales. KdT invests in US biotech and deep tech from pre-seed to Series A with $0.5–5M tickets and backed ZymoChem in the network.

30%confidence

Evidence from the records

  • “$1.5M (NIH SBIR Phase II grant); no public equity round found”
  • “Biotech & life sciences”
  • “GS Futures, KdT Ventures, Cavallo Ventures (existing investors before the Series A)”
If it works
A first equity round financing GMP development and a commercial team.
First step
Ask ZymoChem's CEO for an introduction to KdT Ventures.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

San Francisco early-stage investor pairing technology with science: drug discovery, climate, neurotech and lab automation (ZymoChem).

US serum-free stem-cell culture media sold to UC San Diego, Tufts and Penn State: lab-tools science with revenue at pre-seed.

55%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Serum-free culture media for stem cells”
  • “Range of 11 media and reagents on sale”
Intro path
ZymoChem (Breakout portfolio)
First step
Pitch the media platform as cell-therapy infrastructure.

Physician-founded Austin VC ($250M+ AUM) backing science-driven therapeutics, digital health, industrial biotech and climate companies.

US serum-free stem-cell media with NIH SBIR Phase II — enabling biotech.

50%confidence

Evidence from the records

  • “"Biotech & life sciences"”
  • “Serum-free culture media for stem cells”
  • “Range of 11 media and reagents on sale, used by laboratories (UC San Diego, Tufts, Penn State, Vala Sciences…).”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Send a non-confidential deck.

Investor in Wink Biotherapeutics' US$75K pre-seed (RNA aptamers); profile is undocumented.

US stem-cell culture media with lab customers at pre-seed: early life-science tools.

20%confidence

Evidence from the records

  • “Serum-free culture media for stem cells”
  • “Pre-seed”
Intro path
Wink Biotherapeutics (Dreamward portfolio)
First step
Ask Wink for an intro.

Tennessee's public entrepreneurship organisation; provided an SBIR/STTR matching grant to Enexor Energy.

US NIH SBIR Phase II — SBIR awardee; TN presence unknown.

15%confidence

Evidence from the records

  • “SBIR/STTR matching grant”
  • “Serum-free culture media for stem cells”
  • “Range of 11 media and reagents on sale, used by laboratories (UC San Diego, Tufts, Penn State, Vala Sciences…).”
Intro path
Founder-to-founder intro via Enexor Energy, LLC (network portfolio company of LaunchTN).
First step
Only with a Tennessee presence.

Finnish family office investing in life sciences; joined StemSight's €2.3M seed extension in 2025.

US serum-free culture media for stem cells used by university labs: an enabling tool for cell therapy. US-based.

15%confidence

Evidence from the records

  • “Serum-free culture media for stem cells”
  • “Pre-seed”

Investment analysis

4.8D

Grade D

Rank 48 of 151

Disruption5.0/10
Business model5.0/10
Market3.0/10
Risk(lower is better)5.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Small, healthy company but with limited breakthrough potential; more an acquisition target than a VC case.

Disruption

5/10

Serum-free culture media for stem cells: product innovation in an established category.

Business model

5/10

Range of 11 products sold to laboratories (UC San Diego, Tufts, Penn State): real but modest revenue.

Market

3/10

TAM $0.757bn → base 3; scalability 7/10 (neutral); no international presence: academic customers in the United States → 3/10.

Risk

5/10

Lower is better

Medium risk: product on the market, small amount raised ($1.5M) against Thermo Fisher or STEMCELL.

Strengths

  • Products already sold
  • Scientific expertise

Risks

  • Competition from reagent giants
  • Limited commercial resources

Funding

$1.5M, disclosed
  1. n.d.

    SBIR Phase II grant$1.5M

    NIH (NIGMS)

Amount used in the study. NIH SBIR Phase II grant of $1.5M; no equity round.

Note. $1.5M (NIH SBIR Phase II grant); no public equity round found

Founded in December 2019 in San Diego according to aggregators; Jose M. Morachis is also co-founder and managing partner of Phase Two Ventures (Crunchbase). Funding: only the $1.5M NIH SBIR Phase II grant is confirmed. A research summary attributes to CB Insights $2.75M over 3 rounds, including a $0.25M seed in May 2023 and a seed in 2021, but the CB Insights page consulted concerned another company: figures not verified and not used (conflict to flag). No trace of qualification for a Startup World Cup 2026 regional: neither the San Diego regional (TechCon SoCal, final on 23 May 2026) nor Silicon Valley (won by BioSapien) mentions it in the sources consulted. Reg left null.

Team

  • Steve Rees, PhD

    Co-founder & CEO

    PhD, co-founder and executive of Defined Bioscience (San Diego).

  • Jerome Karpiak, PhD

    Co-founder & VP R&D

    PhD, head of R&D (stem cell culture media).

  • Jose M. Morachis, PhD

    Founder & Chair of the Board

    PhD, founder and chair of the board of directors.

  • Will Alaynick, PhD

    Founder & board member

    PhD, founder and director.

  • Alysson Muotri, PhD

    Co-founder & scientific advisor

    Professor and director of the Stem Cell Program at UC San Diego.

Sources

Identification confidence
medium
Founding year: 2019
2019 (December)
  1. 1definedbioscience.com/
  2. 2instrumentbusinessoutlook.com/?p=312004
  3. 3crunchbase.com/organization/defined-bioscience
  4. 4newsfilecorp.com/release/297930
  5. 5businesswire.com/news/home/20260609019952/en/BioSapien-Wins-2026-Startup-Wor

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet